Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion

Inclusion criteria: * 35 years old ≤ Age ≤ 80 years old * Patients with acute ischemic stroke was diagnosed within 24 hours of onset (time from onset to completion of reperfusion therapy) * Patients with first stroke or prior to stroke onset (mRS score 0-1) * Patients with acute large vessel occlusion (LVO) confirmed by imaging, including the responsible vessel was located in the intracranial internal carotid artery, the T-shaped branch, the M1/M2 segment of the middle cerebral artery, or the A1/A2 segment of the anterior cerebral artery * ASPECTS score ≥ 6 * 6\<NIHSS score ≤ 25 after the onset of this disease * Patients who meet the indications for reperfusion therapy, including mechanical thrombectomy, bridging therapy (intravenous r-tPA thrombolytic therapy), and plan to undergo mechanical thrombectomy * Patients or his/her legal representatives are able to understand and sign the informed consent Exclusion criteria: * Severe consciousness disturbance: NIHSS 1a consciousness level ≥2 points * Patients with definite history of intracranial hemorrhage (such as subarachnoid hemorrhage, cerebral hemorrhage, etc.) * Patients with intracranial tumor, arteriovenous malformation, or aneurysm * Patients with bilateral anterior or posterior circulation ischemic stroke * Patients with large vascular occlusion of rare or unknown etiology, such as dissection, vasculitis, etc. * Patients who have received treatment with dual antiplatelet drugs, tirofiban, warfarin, novel oral anticoagulant, argatroban, snake venom, defibrase, lumbrokinase and other defibrase therapy after the onset of disease * Patients with severe hepatic insufficiency or renal insufficiency and received dialysis for various reasons before randomization (severe hepatic insufficiency is defined as ALT \> 3 × ULN or AST \>3 × ULN; severe renal insufficiency is defined as serum creatinine \>3.0 mg/dL (265.2 μmol/L) or creatinine clearance \< 30 mL/min) * Patients with haemorrhagic diathesis (including but not limited to): platelet count \< 100 × 109/L; heparin treatment within the last 48 hours; taking oral warfarin; taking novel oral anticoagulant; administration with direct thrombin or Xa factor inhibitors; with hereditary hemorrhagic disorders, such as hemophilia * Patients with refractory hypertension that is difficult to be controlled by medication (systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg) * Patients with significant head trauma or stroke within 3 months prior to randomization * Patients who have received intracranial or spinal surgery within 3 months prior to randomization * Patients with history of major surgery or serious physical trauma within 1 month prior to randomization * Patients with hemorrhagic retinopathy * Male subjects (or their partners) or female subjects who had planned to have a child during the whole study period and within 3 months after the end of the study period or were unwilling to use one or more non-drug contraceptive methods (e.g., complete abstinence, condoms, ligation, etc.) during the study period * Patients with contraindications to known contrast agent or other contrast agents; subjects who are allergic to cilostazol or dexborneol * Patients who plan to receive other surgical or intervention therapy within 3 months, which might require discontinuation of the study drugs * Patients with advanced disease, leading to life expectancy of \< 6 months * Patients who have received treatment of investigational drug or device within 3 months * Other conditions where it is not suitable for patients to participate in the clinical trial, such as inability to understand and/or follow the study procedures and/or follow-up schedule due to psychiatric disorders or cognitive/emotional disorders, or contraindications to thrombectomy or MRI, etc.